Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dendritic cell vaccine - Bioclones/AIM ImmunoTech

Next Previous
Drug Profile

Dendritic cell vaccine - Bioclones/AIM ImmunoTech

Alternative Names: Cancer vaccine - Bioclones; dendritic-cell-vaccine- AIM Immunotech; Patient-specific DC immunotherapy vaccine - Bioclones/AIM ImmunoTech

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioclones
  • Developer AIM ImmunoTech; Bioclones
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ovarian cancer
  • No development reported Breast cancer; Cancer; Prostate cancer

Most Recent Events

  • 14 May 2025 Roswell Park Cancer Institute and AIM ImmunoTech suspends a phase I/II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater, Recurrent, Late-stage disease) in USA (Intradermal) (NCT02432378)
  • 23 Aug 2019 Hemispherx Biopharma is now called AIM ImmunoTech
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Breast-cancer in South Africa (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top